{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:50:51Z","timestamp":1792900251476,"version":"4.5.0"},"reference-count":44,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,4,9]]},"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To examine the population-wide overdose risk emerging from the prescription of methadone and buprenorphine for opioid substitution treatment in England and Wales.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective administrative data study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>National databases for England and Wales.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants\/cases<\/jats:title>\n                  <jats:p>Drug-related mortality data were drawn from the Office for National Statistics, and prescription data for methadone and buprenorphine were obtained from the National Health Service for the years 2007\u20132012. During this 6-year period, a total of 2366 methadone-related deaths and 52 buprenorphine-related deaths were registered, corresponding to 17\u2005333\u2005163 methadone and 2\u2005602\u2005374 buprenorphine prescriptions issued. The analysis encompassed poisoning deaths among members of the wider population of England and Wales who consumed, but were not prescribed these medications, in addition to patients prescribed methadone or buprenorphine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Mortality risk: substance-specific overdose rate per 1000 prescriptions issued; relative risk ratio of methadone in relation to buprenorphine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the years 2007\u20132012, the pooled overdose death rate was 0.137\/1000 prescriptions of methadone, compared to 0.022\/1000 prescriptions of buprenorphine (including buprenorphine-naloxone). The analysis generated a relative risk ratio of 6.23 (95% CI 4.79\u00a0to 8.10) of methadone in relation to buprenorphine. UK Borders Agency data were taken into consideration and revealed that only negligible amounts of methadone and buprenorphine were seized on entering UK territory between 2007 and 2012, suggesting domestic diversion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our analysis of the relative safety of buprenorphine and methadone for opioid substitution treatment reveals that buprenorphine is six times safer than methadone with regard to overdose risk among the general population. Clinicians should be aware of the increased risk of prescribing methadone, and tighter regulations are needed to prevent its diversion.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-007629","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T17:00:03Z","timestamp":1715792403000},"page":"e007629","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":55,"title":["The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales"],"prefix":"10.1136","volume":"5","author":[{"given":"Dave","family":"Marteau","sequence":"first","affiliation":[{"name":"Health and Human Development, University of East London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8478-2067","authenticated-orcid":false,"given":"Rebecca","family":"McDonald","sequence":"additional","affiliation":[{"name":"Addictions Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7441-2102","authenticated-orcid":false,"given":"Kamlesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Health and Human Development, University of East London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2015,5,29]]},"reference":[{"key":"2025101812220647000_5.5.e007629.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"2025101812220647000_5.5.e007629.2","unstructured":"ACMD. Consideration of Naloxone. London: Home Office. London, England: The Stationery Office, 2012."},{"key":"2025101812220647000_5.5.e007629.3","unstructured":"Office H. Drug Strategy 2010. Reducing Demand, Restricting Supply, Building Recovery: Supporting People to Live a Drug-free Life 2010 [30 May 2014]. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/118336\/drug-strategy-2010.pdf"},{"key":"2025101812220647000_5.5.e007629.4","unstructured":"(NICE) NIfHCE. NICE technology appraisal guidance 114, Methadone and buprenorphine for the management of opioid dependence, 2007 [25 April 2014]. http:\/\/www.nice.org.uk\/TA114"},{"key":"2025101812220647000_5.5.e007629.5","doi-asserted-by":"crossref","unstructured":"Wesson DR . Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S. J Psychoactive Drugs 2004;(Suppl 2):119\u201328. doi:10.1080\/02791072.2004.10400047","DOI":"10.1080\/02791072.2004.10400047"},{"key":"2025101812220647000_5.5.e007629.6","unstructured":"Mattick RP , Breen C , Kimber J , et al . Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009, Issue 3: CD002209. doi:10.1002\/14651858.CD002209.pub2. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD002209.pub2\/pdf"},{"key":"2025101812220647000_5.5.e007629.7","doi-asserted-by":"crossref","unstructured":"Mattick RP , Kimber J , Breen C , et al . Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2 (2): CD002207. doi:10.1002\/14651858.CD002207.pub4. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD002207.pub4\/pdf","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"2025101812220647000_5.5.e007629.8","doi-asserted-by":"crossref","unstructured":"Cornish R , Macleod J , Strang J , et al . Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341. doi:10.1136\/bmj.c5475","DOI":"10.1136\/bmj.c5475"},{"key":"2025101812220647000_5.5.e007629.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3172"},{"key":"2025101812220647000_5.5.e007629.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2007.11.003"},{"key":"2025101812220647000_5.5.e007629.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb03057.x"},{"key":"2025101812220647000_5.5.e007629.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01050.x"},{"key":"2025101812220647000_5.5.e007629.13","unstructured":"(UKDP) UDPC. An Analysis of UK Drug Policy 2007 [May 30 2014]. http:\/\/www.ukdpc.org.uk\/publication\/an-analysis-uk-drug-policy\/"},{"key":"2025101812220647000_5.5.e007629.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00376.x"},{"key":"2025101812220647000_5.5.e007629.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01688.x"},{"key":"2025101812220647000_5.5.e007629.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(02)00304-1"},{"key":"2025101812220647000_5.5.e007629.17","doi-asserted-by":"publisher","DOI":"10.1002\/hup.698"},{"key":"2025101812220647000_5.5.e007629.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1122-4"},{"key":"2025101812220647000_5.5.e007629.19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7517-9-3","article-title":"The nature of methadone diversion in England: a Merseyside case study","volume":"9","author":"Duffy","year":"2012","journal-title":"Harm Reduct J"},{"key":"2025101812220647000_5.5.e007629.20","first-page":"240","article-title":"Opioid overdose prevention and naloxone distribution in Rhode Island","volume":"94","author":"Yokell","year":"2011","journal-title":"Med Health R I"},{"key":"2025101812220647000_5.5.e007629.21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00294.x"},{"key":"2025101812220647000_5.5.e007629.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c4851"},{"key":"2025101812220647000_5.5.e007629.23","unstructured":"Corkery J , Claridge H , Loi B , et al . Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2012 . London: St George's University, 2013."},{"key":"2025101812220647000_5.5.e007629.24","unstructured":"Ghodse H , Corkery J , Claridge H , et al . Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2011 . London: St George's University, 2012."},{"key":"2025101812220647000_5.5.e007629.25","unstructured":"Ghodse H , Corkery J , Ahmed K , et al . Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), UK Annual Report 2010 . London: St George's University, 2011."},{"key":"2025101812220647000_5.5.e007629.26","unstructured":"Ghodse H , Corkery J , Oyefeso A , et al . Drug-related Deaths in the UK, National Programme on Substance Abuse Deaths (np-SAD), International Centre for Drug Policy (ICDP), UK Annual Report 2009 . London: St George's University, 2010."},{"key":"2025101812220647000_5.5.e007629.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0379-0738(00)00282-6"},{"key":"2025101812220647000_5.5.e007629.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.03.020"},{"key":"2025101812220647000_5.5.e007629.29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.1.45"},{"key":"2025101812220647000_5.5.e007629.30","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490440780"},{"key":"2025101812220647000_5.5.e007629.31","unstructured":"ONS. Statistical bulletin: Deaths related to drug poisoning in England and Wales, 2012, 2013 [May 30, 2014]. http:\/\/www.ons.gov.uk\/ons\/rel\/subnational-health3\/deaths-related-to-drug-poisoning\/2012\/stb---deaths-related-to-drug-poisoning-2012.html"},{"key":"2025101812220647000_5.5.e007629.32","unstructured":"Wilson DB . Practical Meta-Analysis Effect Size Calculator 2014 [June 31, 2014]. http:\/\/www.campbellcollaboration.org\/resources\/effect_size_input.php"},{"key":"2025101812220647000_5.5.e007629.33","unstructured":"Office H . Seizures of Drugs in England and Wales, 2011\/12, Second Edition. London: Home Office, 2012."},{"key":"2025101812220647000_5.5.e007629.34","first-page":"871","article-title":"Buprenorphine\/naloxone versus methadone in opioid dependence: a longitudinal survey","volume":"15","author":"Curcio","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025101812220647000_5.5.e007629.35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","article-title":"Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers","volume":"179","author":"Neri","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"2025101812220647000_5.5.e007629.36","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490440799"},{"key":"2025101812220647000_5.5.e007629.37","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2003.00335.x"},{"key":"2025101812220647000_5.5.e007629.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(00)00163-0"},{"key":"2025101812220647000_5.5.e007629.39","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","article-title":"Comparison of buprenorphine and methadone in the treatment of opioid dependence","volume":"151","author":"Strain","year":"1994","journal-title":"Am J Psychiatry"},{"key":"2025101812220647000_5.5.e007629.40","doi-asserted-by":"publisher","DOI":"10.1007\/BF02247469"},{"key":"2025101812220647000_5.5.e007629.41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874473711104010028","article-title":"Buprenorphine and buprenorphine\/naloxone diversion, misuse, and illicit use: an international review","volume":"4","author":"Yokell","year":"2011","journal-title":"Current Drug Abuse Rev"},{"key":"2025101812220647000_5.5.e007629.42","unstructured":"administrations DoHEatd. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health (England), the Scottish Government, Welsh Assembly Government and Northern Ireland Executive, 2007."},{"key":"2025101812220647000_5.5.e007629.43","unstructured":"Dart R . Buprenorphine. College on Problems of Drug Dependence, 74th Annual Scientific Meeting. Palm Springs, California, 2012."},{"key":"2025101812220647000_5.5.e007629.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2013.06.017"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-007629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T19:22:13Z","timestamp":1760815333000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-007629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,29]]},"published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1136\/bmjopen-2015-007629"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-007629","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}